NCT07623642

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-06-02Est. Completion: 2028-06-15

Enrollment target: 227 participants

Locations

Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Contact

Shanghai Xunbaihui Biotechnologyclinicaltrials@gv20tx.com +8615800557307

Other microbiome trials you might be interested in

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2Recruiting

Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial CarcinomaSalivary Gland CancerPancreatic CancerHER-2 Protein Overexpression

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with p…

Prescott, United StatesEst. completion Dec 31, 2026

View Trial →

Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.